Advertisement

pädiatrie hautnah

, Volume 24, Issue 4, pp 264–267 | Cite as

Neue Impfung gegen Meningokokken B

Schutz vor der in Europa häufigsten Serogruppe
  • Tobias Tenenbaum
  • Markus Knuf
Zertifizierte Fortbildung
  • 16 Downloads

Derzeit sind in Deutschland Polysaccharid- und Konjugatimpfstoffe gegen Meningokokken der Serogruppe A, C, W135 und Y verfügbar. Ein neuer rekombinanter 4-Komponenten-Meningokokken-B-Impfstoff (4CMenB) befindet sich aktuell im europäischen Zulassungsverfahren. Dieser deckt einen Großteil der in Deutschland zirkulierenden Stämme ab. Immunogenität und Sicherheit sind für unterschiedlichste Impfschemata im Säuglingsalter und darüber hinaus untersucht, ebenso die Koadministrationen mit Standardimpfstoffen.

Literatur

  1. 1.
    Pollard AJ, Nadel S, Ninis N, Faust SN, Levin M. Emergency management of meningococcal disease: eight years on. Arch Dis Child 2007; 92: 283–286PubMedCrossRefGoogle Scholar
  2. 2.
    European Union Invasive Bacterial Infections Surveillance Network. Invasive Neisseria meningitidis in Europe (2006) [Accessed 06.07.2012]. Available at http://www.hpa-bioinformatics.org.uk/euibis/neisseria.htm Google Scholar
  3. 3.
    WHO Strategic Advisory Group of Experts on Immunization (SAGE). Meningococcal vaccines: WHO position paper. Weekly Epidemiological Record 2011; 86: 521–540Google Scholar
  4. 4.
    Epidemiologisches Bulletin, Nr.32, 2008, http://www.rki.de
  5. 5.
    Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus I–V. J Exp Med 1969; 129: 1307–1395PubMedCrossRefGoogle Scholar
  6. 6.
    Granoff DM, Pollard AJ. Reconsideration of the use of meningococcal polysaccharide vaccine. Pediatr Infect Dis J 2007; 26: 716–722PubMedCrossRefGoogle Scholar
  7. 7.
    Snape D, Pollard AJ. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis 2005; 5: 21–30PubMedCrossRefGoogle Scholar
  8. 8.
    Conterno LO, Silva Filho CR, Rüggeberg JU, Heath PT. Conjugate vaccines for preventing meningococcal C meningitis and septicaemia. Cochrane Database Syst Rev 2006; 19; 3: CD 001834Google Scholar
  9. 9.
    Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroupCconjugate vaccine 4 years after introduction. Lancet 2004; 364: 365–367PubMedCrossRefGoogle Scholar
  10. 10.
    Jackson LA, Jacobson RM, Reisinger KS, Anemona A, Danzig LE, Dull PM. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr Infect Dis J 2009; 28: 86–91PubMedCrossRefGoogle Scholar
  11. 11.
    Reisinger KS, Black S, Stoddard JJ. Optimizing protection against meningococcal disease. Clin Pediatr (Phila) 2010; 49: 586–597CrossRefGoogle Scholar
  12. 12.
    Bai X, Findlow J, Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther 2001;11: 969–985CrossRefGoogle Scholar
  13. 13.
    Daten des Nationalen Referenzzentrums für Meningokokken für das Jahr 2011 (http://www.meningococcus.uni-wuerzburg.de/startseite/berichte/daten_2011/)
  14. 14.
    Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, Moxon ER, Stella M, Comanducci M, Bambini S, Muzzi A, Andrews W, Chen J, Santos G, Santini L, Boucher P, Serruto D, Pizza M, Rappuoli R, Giuliani MM. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A. 2011; 107: 19490–19495CrossRefGoogle Scholar
  15. 15.
    Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Becker B, Kieninger D, Prymula R, Dull P, Ypma E, Toneatto D, Kimura A, Pollard AJ; European MenB Vaccine Study Group. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012; 307: 573–582PubMedCrossRefGoogle Scholar
  16. 16.
    Borrow R, Carlone GM, Rosenstein N, Blake M, Feavers I, Martin D, Zollinger W, Robbins J, Aaberge I, Granoff DM, Miller E, Plikaytis B, van Alphen L, Poolman J, Rappuoli R, Danzig L, Hackell J, Danve B, Caulfield M, Lambert S, Stephens D. Neisseria meningitidis group B correlates of protection and assay standardization-international meeting report Emory University, Atlanta, Georgia, United States, 16–17 March 2005. Vaccine 2006; 24: 5093–5107PubMedCrossRefGoogle Scholar
  17. 17.
    Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist AC, Gershman KA, Vazquez M, Bennett NM, Reingold A, Thomas A, Glode MP, Zell ER, Jorgensen JH, Beall B, Schuchat A. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006; 368: 1495–1502PubMedCrossRefGoogle Scholar
  18. 18.
    Dagan R, Givon-Lavi N, Greenberg D, Fritzell B, Siegrist CA. Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy. J Infect Dis 2006; 201: 1570–1579CrossRefGoogle Scholar
  19. 19.
    Snape MD, Dawson T, Oster P, Evans A, John TM, Ohene-Kena B, Findlow J, Yu LM, Borrow R, Ypma E, Toneatto D, Pollard AJ. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J 29: e71–79Google Scholar
  20. 20.
    Santolaya ME et al.; V72P10 Meningococcal B Adolescent Vaccine Study group. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012; 379: 617–624PubMedCrossRefGoogle Scholar
  21. 21.
    Epidemiologisches Bulletin 30–33/2006, http://www.rki.de
  22. 22.
    Epidemiologisches Bulletin 7/2007, http://www.rki.de

Copyright information

© Urban & Vogel 2012

Authors and Affiliations

  • Tobias Tenenbaum
    • 1
  • Markus Knuf
    • 2
  1. 1.Universitätsklinik für Kinder- und JugendmedizinMannheimDeutschland
  2. 2.Klinik für Kinder und Jugendliche Klinikum der Landeshauptstadt Wiesbaden HSKWiesbadenDeutschland

Personalised recommendations